Table 2 provides an overview of exogenous albumin-based cancer therapeutics. Based on the albumin binding strategy, exogenous albumin-based cancer therapeutics can be divided in micro- or nanoparticle formulations, covalent conjugations and genetic fusions (Figure 5). The gene discussed is ALB; the disease is cancer.